PARP1 and breast cancer: Unfortunately, preclinical and clinical evidence has shown that not all patients with BRCA-mutated tumors respond to PARP inhibitors [18], and PARP inhibitors are also effective for breast cancer cells lacking BRCA mutations [21, 22].